Key result
Lower plasma melatonin linked to ~250% higher mortality in treatment-naïve PAH.
Why the study?
Endogenous melatonin levels in treatment-naïve patients with pulmonary hypertension and their clinical significance were unknown.
Do lower endogenous plasma melatonin levels predict worse long-term survival in treatment-naïve patients with pulmonary arterial hypertension?
Observational (n=175)
No
Do lower endogenous plasma melatonin levels predict worse long-term survival in treatment-naïve patients with pulmonary arterial hypertension?
Lower endogenous plasma melatonin levels are associated with worse long-term survival in treatment-naïve patients with pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
Does not support routine melatonin assessment in PAH; hypothesis-generating for its prognostic value, needing prospective validation.
Exogenous melatonin has been reported to be beneficial in the treatment of pulmonary hypertension (PH) in animal models. Multiple mechanisms are involved, with melatonin exerting anti-oxidant and anti-inflammatory effects, as well as inducing vasodilation and cardio-protection. However, endogenous levels of melatonin in treatment-naïve patients with PH and their clinical significance are still unknown. Plasma levels of endogenous melatonin were measured by liquid chromatography-tandem mass spectrometry in PH patients (n = 64, 43 pulmonary arterial hypertension (PAH) and 21 chronic thromboembolic PH (CTEPH)) and healthy controls (n = 111). Melatonin levels were higher in PH, PAH, and CTEPH patients when compared with controls (Median 118.7 (IQR 108.2–139.9), 118.9 (109.3–147.7), 118.3 (106.8–130.1) versus 108.0 (102.3–115.2) pM, respectively, p all <0.001). The mortality was 26% (11/43) in the PAH subgroup during a long-term follow-up of 42 (IQR: 32–58) months. Kaplan–Meier analysis showed that, in the PAH subgroup, patients with melatonin levels in the 1st quartile (<109.3 pM) had a worse survival than those in quartile 2–4 (Mean survival times were 46 (95% CI: 30–65) versus 68 (58–77) months, Log-rank, p = 0.026) with an increased hazard ratio of 3.5 (95% CI: 1.1–11.6, p = 0.038). Endogenous melatonin was increased in treatment-naïve patients with PH, and lower levels of melatonin were associated with worse long-term survival in patient with PAH.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2020) conducted an observational in Pulmonary Arterial Hypertension (n=175). Lower plasma melatonin levels (<109.3 pM) vs. Higher plasma melatonin levels (≥109.3 pM) was evaluated on All-cause mortality (HR 3.5, 95% CI 1.1-11.6, p=0.038). Lower endogenous plasma melatonin levels were associated with worse long-term survival in treatment-naïve patients with pulmonary arterial hypertension, with a.5 for mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: